ArticleLife science alliance2025
GSK3A promotes human adenovirus replication and phosphorylates viral L4-22K protein.
Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- CMGC Kinases in Viral Infection and Human Disease.Pathogens (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human adenovirus B7 (HAdV-B7) is a significant respiratory pathogen in children, associated with substantial morbidity and mortality. Despite its clinical importance, the molecular mechanisms of HAdV-B7-host interaction remain poorly elucidated. In this study, we performed a high-throughput gain-of-function cDNA library screening and identified glycogen synthase kinase 3α (GSK3A) as a key proviral factor facilitating HAdV-B7 replication. The overexpression of GSK3A enhanced viral replication, whereas knockdown or knockout inhibited it. Furthermore, the kinase-active S21A mutant significantly augmented viral replication, whereas the kinase-inactive Y279A and K148A mutants of GSK3A failed to support it, highlighting the importance of its kinase activity on HAdV-B7 replication. Notably, phosphoproteomic and co-immunoprecipitation assays (co-IP) revealed that GSK3A phosphorylates viral L4-22K protein at S78 and S81 residues in a partially kinase-dependent manner. Using structure modeling, protein-protein docking, and truncation assays, we mapped the interaction between GSK3A's kinase domain and the 92-168 aa region of the viral L4-22K protein. In addition, GSK3A acts as a broad-spectrum proviral factor for respiratory HAdV, particularly for Species B, corresponding to a high similarity in L4-22K sequences. As a result, we identified GSK3A as a crucial proviral host factor for HAdV replication and provided a promising avenue for targeting GSK3A in the development of antiviral therapies against HAdV infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.